BioStock Investor Meeting: Interview with WntResearch

The last few months have been eventful for cancer therapy company WntResearch. In August, the company announced unexpected and promising findings with the candidate Foxy-5 in the phase II study Neofox, which prompted the company to change its plans for the study. CEO Pernilla Sandwall told us more about the updated study strategy in connection with the BioStock Investor Meeting.

See the full interview at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-wntresearch/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se